3lwb

Crystal Structure of apo D-alanine:D-alanine Ligase (Ddl) from Mycobacterium tuberculosis

spinqualitylabelsall models 3lwb, resolution 2.10Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 3lwb is a 2 chain structure with sequence from Mycobacterium tuberculosis. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: NO3 Gene: ddl, ddlA, MT3059, MTCY349.06, Rv2981c (Mycobacterium tuberculosis) Activity: D-alanine--D-alanine ligase, with EC number 6.3.2.4 Resources: FirstGlance, OCA, RCSB, PDBsum Function [DDL_MYCTU] Cell wall formation (By similarity). Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMed D-alanine:D-alanine ligase (EC 6.3.2.4, Ddl) catalyzes the ATP driven ligation of two D-alanine (D-ala) molecules to form the D-alanyl:D-alanine dipeptide. This molecule is a key building block in peptidoglycan biosynthesis making Ddl an attractive target for drug development. D-cycloserine (DCS), an analog of D-ala and a prototype Ddl inhibitor, has shown promise for the treatment of tuberculosis. Here, we report the crystal structure of the Mycobacterium tuberculosis Ddl at a resolution of 2.1 A. This structure indicates that Ddl is a dimer and consists of three discrete domains; the ligand binding cavity is at the intersection of all three domains and conjoined by several loop regions. The M. tuberculosis apo Ddl structure shows a novel conformation that has not yet been observed in Ddl enzymes from other species. The nucleotide and D-alanine binding pockets are flexible, requiring significant structural rearrangement of the bordering regions for entry and binding of both ATP and D-ala molecules. Solution affinity and kinetic studies showed that DCS interacts with Ddl in a manner similar to D-ala. Each ligand binds to two binding sites that have significant differences in affinity with the first binding site exhibiting high affinity. DCS inhibits the enzyme with an IC50 of 0.37 mM under standard assay conditions, implicating a preferential and weak inhibition at the second, lower affinity, binding site. Moreover, DCS binding is tighter at higher ATP concentrations. The crystal structure illustrates potential drugable sites that may result in the development of more effective Ddl inhibitors. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine Ligase: a target of the anti-tuberculosis drug D-cycloserine.,Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC Antimicrob Agents Chemother. 2010 Oct 18. PMID:20956591 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also D-alanine-D-alanine ligase

Proteopedia Page Contributors and Editors (what is this?)

OCA